158 related articles for article (PubMed ID: 31629038)
1. Predicting drug release kinetics from nanocarriers inside dialysis bags.
Yu M; Yuan W; Li D; Schwendeman A; Schwendeman SP
J Control Release; 2019 Dec; 315():23-30. PubMed ID: 31629038
[TBL] [Abstract][Full Text] [Related]
2. General method for the quantification of drug loading and release kinetics of nanocarriers.
Schwarzl R; Du F; Haag R; Netz RR
Eur J Pharm Biopharm; 2017 Jul; 116():131-137. PubMed ID: 28017797
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic model and analysis of doxorubicin release from liposomal formulations.
Fugit KD; Xiang TX; Choi du H; Kangarlou S; Csuhai E; Bummer PM; Anderson BD
J Control Release; 2015 Nov; 217():82-91. PubMed ID: 26310713
[TBL] [Abstract][Full Text] [Related]
4. A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release.
Nagpal S; Braner S; Modh H; Tan AXX; Mast MP; Chichakly K; Albrecht V; Wacker MG
Eur J Pharm Biopharm; 2020 Aug; 153():257-272. PubMed ID: 32589926
[TBL] [Abstract][Full Text] [Related]
5. Reliable Kinetics for Drug Delivery with a Microfluidic Device Integrated with the Dialysis Bag.
Esmaeili J; Barati A; Salehi E; Ai J
Mol Pharm; 2023 Feb; 20(2):1129-1137. PubMed ID: 36652296
[TBL] [Abstract][Full Text] [Related]
6. A New Method for Evaluating Actual Drug Release Kinetics of Nanoparticles inside Dialysis Devices via Numerical Deconvolution.
Zhou Y; He C; Chen K; Ni J; Cai Y; Guo X; Wu XY
J Control Release; 2016 Dec; 243():11-20. PubMed ID: 27693750
[TBL] [Abstract][Full Text] [Related]
7. Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method.
Modi S; Anderson BD
Mol Pharm; 2013 Aug; 10(8):3076-89. PubMed ID: 23758289
[TBL] [Abstract][Full Text] [Related]
8. Assessing the drug release from nanoparticles: Overcoming the shortcomings of dialysis by using novel optical techniques and a mathematical model.
Xie L; Beyer S; Vogel V; Wacker MG; Mäntele W
Int J Pharm; 2015 Jul; 488(1-2):108-19. PubMed ID: 25847513
[TBL] [Abstract][Full Text] [Related]
9. Comparison of different in vitro release methods used to investigate nanocarriers intended for dermal application.
Balzus B; Colombo M; Sahle FF; Zoubari G; Staufenbiel S; Bodmeier R
Int J Pharm; 2016 Nov; 513(1-2):247-254. PubMed ID: 27628784
[TBL] [Abstract][Full Text] [Related]
10. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice.
Wang H; Zheng M; Gao J; Wang J; Zhang Q; Fawcett JP; He Y; Gu J
Talanta; 2020 Feb; 208():120358. PubMed ID: 31816795
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Dialysis- and Solvatofluorochromism-Based Methods to Determine Drug Release Rates from Polymer Nanoassemblies.
Reichel D; Bae Y
Pharm Res; 2017 Feb; 34(2):394-407. PubMed ID: 27873146
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of Cross-linked Poly (N-isopropylacrylamide) Magnetic Nano Composite for Application in the Controlled Release of Doxorubicin.
Kaamyabi S; Badrian A; Akbarzadeh A
Pharm Nanotechnol; 2017; 5(1):67-75. PubMed ID: 28948911
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
[TBL] [Abstract][Full Text] [Related]
14. Rapid Analysis of DOXIL Stability and Drug Release from DOXIL by HPLC Using a Glycidyl Methacrylate-Coated Monolithic Column.
Kimoto A; Watanabe A; Yamamoto E; Higashi T; Kato M
Chem Pharm Bull (Tokyo); 2017; 65(10):945-949. PubMed ID: 28966279
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of polydopamine modified and conventional chemical synthesis method in doxorubicin liposomes form the aspect of tumor targeted therapy.
Bi D; Zhao L; Li H; Guo Y; Wang X; Han M
Int J Pharm; 2019 Mar; 559():76-85. PubMed ID: 30677481
[TBL] [Abstract][Full Text] [Related]
17. Controlled release of doxorubicin from polyethylene glycol functionalized melanin nanoparticles for breast cancer therapy: Part I. Production and drug release performance of the melanin nanoparticles.
Ozlu B; Kabay G; Bocek I; Yilmaz M; Piskin AK; Shim BS; Mutlu M
Int J Pharm; 2019 Oct; 570():118613. PubMed ID: 31415880
[TBL] [Abstract][Full Text] [Related]
18. PEGylated hyperbranched polyphosphoester based nanocarriers for redox-responsive delivery of doxorubicin.
Chen C; Zheng P; Cao Z; Ma Y; Li J; Qian H; Tao W; Yang X
Biomater Sci; 2016 Mar; 4(3):412-7. PubMed ID: 26626655
[TBL] [Abstract][Full Text] [Related]
19. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
20. Aptamer-based liposomes improve specific drug loading and release.
Plourde K; Derbali RM; Desrosiers A; Dubath C; Vallée-Bélisle A; Leblond J
J Control Release; 2017 Apr; 251():82-91. PubMed ID: 28238787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
